Treating Symptomatic Hyperprolactinemia in Women with Schizophrenia: Presentation of the Ongoing DAAMSEL Clinical Trial (Dopamine Partial Agonist, Aripiprazole, for the Management of Symptomatic ELevated Prolactin)

Overview

Journal BMC Psychiatry

Publisher Biomed Central

Specialty Psychiatry

Date 2013 Aug 24

PMID 23968123

Citations 15

Authors

Deanna L Kelly

Heidi J Wehring

Amber K Earl

Kelli M Sullivan

Faith B Dickerson

Stephanie Feldman

Robert P McMahon

Robert W Buchanan

Dale Warfel

William R Keller

Bernard A Fischer

Joo-Cheol Shim

Affiliations

Soon will be listed here.

Abstract

Prolactin elevations occur in people treated with antipsychotic medications and are often much higher in women than in men. Hyperprolactinemia is known to cause amenorrhea, oligomenorrhea, galactorrhea and gynecomastia in females and is also associated with sexual dysfunction and bone loss. These side effects increase risk of antipsychotic nonadherence and suicide and pose significant problems in the long term management of women with schizophrenia. In this manuscript, we review the literature on prolactin; its physiology, plasma levels, side effects and strategies for treatment. We also present the rationale and protocol for an ongoing clinical trial to treat symptomatic hyperprolactinemia in premenopausal women with schizophrenia. More attention and focus are needed to address these significant side effects and help the field better personalize the treatment of women with schizophrenia.

Citing Articles

Comparative Study of Extrapyramidal Side Effects, Sexual Dysfunctions and Hyperprolactinaemia Using Typical and Atypical Antipsychotic Medications Among Patients with Schizophrenia in Maiduguri.

Shettima F, Wakil M, Sheikh T, Rabbebe I, Abdulaziz M, Jidda S Niger Med J. 2024; 64(5):612-626.

PMID: 38962106 PMC: 11218855. DOI: 10.60787/NMJ-64-5-311.

Antipsychotics-related hyperprolactinaemia among patients with schizophrenia in Maiduguri.

Shettima F, Wakil M, Sheikh T, Abdulaziz M, Wakawa I, Beida O S Afr J Psychiatr. 2024; 30:2133.

PMID: 38444408 PMC: 10912972. DOI: 10.4102/sajpsychiatry.v30i0.2133.

Physical health monitoring for people with schizophrenia.

Castle D, Li A Aust Prescr. 2023; 46(4):75-79.

PMID: 38152317 PMC: 10751083. DOI: 10.18773/austprescr.2023.024.

Prolactin Level Changes according to Atypical Antipsychotics Use: A Study Based on Clinical Data Warehouse.

Kim S, Jeong J, Um Y, Kim T, Seo H, Hong S Clin Psychopharmacol Neurosci. 2023; 21(4):769-777.

PMID: 37859450 PMC: 10591174. DOI: 10.9758/cpn.23.1057.

Peony-Glycyrrhiza Decoction for Antipsychotic-Related Hyperprolactinemia in Patients with Schizophrenia: A Randomized Controlled Trial.

Wang Z, Zheng Y, Fan Y, Fan Y, Su X, Wang B Neuropsychiatr Dis Treat. 2023; 19:929-938.

PMID: 37089913 PMC: 10120814. DOI: 10.2147/NDT.S408314.

References

Shim J, Shin J, Kelly D, Jung D, Seo Y, Liu K . Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial. Am J Psychiatry. 2007; 164(9):1404-10. DOI: 10.1176/appi.ajp.2007.06071075. View

Casey D, Carson W, Saha A, Liebeskind A, Ali M, Jody D . Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study. Psychopharmacology (Berl). 2003; 166(4):391-9. DOI: 10.1007/s00213-002-1344-3. View

Marken P, Haykal R, FISHER J . Management of psychotropic-induced hyperprolactinemia. Clin Pharm. 1992; 11(10):851-6. View

Gudelsky G . Tuberoinfundibular dopamine neurons and the regulation of prolactin secretion. Psychoneuroendocrinology. 1981; 6(1):3-16. DOI: 10.1016/0306-4530(81)90044-5. View

Kikuchi T, Iwamoto K, Sasada K, Aleksic B, Yoshida K, Ozaki N . Sexual dysfunction and hyperprolactinemia in Japanese schizophrenic patients taking antipsychotics. Prog Neuropsychopharmacol Biol Psychiatry. 2011; 37(1):26-32. DOI: 10.1016/j.pnpbp.2011.11.016. View

MOLONEY P, Elliott G, JOHNSON H . Experiences with priapism. J Urol. 1975; 114(1):72-6. DOI: 10.1016/s0022-5347(17)66946-5. View

Lenton E, Brook L, Sobowale O, Cooke I . Prolactin concentrations in normal menstrual cycles and conception cycles. Clin Endocrinol (Oxf). 1979; 10(4):383-91. DOI: 10.1111/j.1365-2265.1979.tb02093.x. View

Keks N, Copolov D, Singh B . Abnormal prolactin response to haloperidol challenge in men with schizophrenia. Am J Psychiatry. 1987; 144(10):1335-7. DOI: 10.1176/ajp.144.10.1335. View

King D, Link C, Kowalcyk B . A comparison of bd and tid dose regimens of quetiapine (Seroquel) in the treatment of schizophrenia. Psychopharmacology (Berl). 1998; 137(2):139-46. DOI: 10.1007/s002130050603. View

10.

Haddad P, Hellewell J, Wieck A . Antipsychotic induced hyperprolactinaemia: a series of illustrative case reports. J Psychopharmacol. 2002; 15(4):293-5. DOI: 10.1177/026988110101500408. View

11.

Jung D, Seo Y, Park J, Jeong C, Conley R, Kelly D . The prevalence of hyperprolactinemia after long-term haloperidol use in patients with chronic schizophrenia. J Clin Psychopharmacol. 2005; 25(6):613-5. DOI: 10.1097/01.jcp.0000186738.84276.9f. View

12.

Beumont P, Gelder M, Friesen G, Harris G, MACKINNON P, MANDELBROTE B . The effects of phenothiazines on endocrine function: I. Patients with inappropriate lactation and amenorrhoea. Br J Psychiatry. 1974; 124(0):413-9. DOI: 10.1192/bjp.124.5.413. View

13.

Abu-Tair F, Kopitz J, Bergemann N . Clozapine augmented with aripiprazole in 5 patients with schizophrenia. J Clin Psychopharmacol. 2006; 26(6):669-71. DOI: 10.1097/01.jcp.0000246206.65411.f5. View

14.

Meltzer H, Fang V . The effect of neuroleptics on serum prolactin in schizophrenic patients. Arch Gen Psychiatry. 1976; 33(3):279-86. DOI: 10.1001/archpsyc.1976.01770030003001. View

15.

Mitsonis C, Dimopoulos N, Mitropoulos P, Kararizou E, Katsa A, Tsakiris F . Aripiprazole augmentation in the management of residual symptoms in clozapine-treated outpatients with chronic schizophrenia: An open-label pilot study. Prog Neuropsychopharmacol Biol Psychiatry. 2006; 31(2):373-7. DOI: 10.1016/j.pnpbp.2006.09.015. View

16.

Ucok A, Incesu C, Aker T, Erkoc S . Sexual dysfunction in patients with schizophrenia on antipsychotic medication. Eur Psychiatry. 2007; 22(5):328-33. DOI: 10.1016/j.eurpsy.2007.01.001. View

17.

Karunakaran K, Tungaraza T, Harborne G . Is clozapine-aripiprazole combination a useful regime in the management of treatment-resistant schizophrenia?. J Psychopharmacol. 2006; 21(4):453-6. DOI: 10.1177/0269881106068289. View

18.

Liu-Seifert H, Kinon B, Tennant C, Sniadecki J, Volavka J . Sexual dysfunction in patients with schizophrenia treated with conventional antipsychotics or risperidone. Neuropsychiatr Dis Treat. 2009; 5:47-54. PMC: 2695222. DOI: 10.2147/ndt.s4766. View

19.

Yuan H, Wang C, Sze C, Tong Y, Tan Q, Feng X . A randomized, crossover comparison of herbal medicine and bromocriptine against risperidone-induced hyperprolactinemia in patients with schizophrenia. J Clin Psychopharmacol. 2008; 28(3):264-370. DOI: 10.1097/JCP.0b013e318172473c. View

20.

Perkins D . Predictors of noncompliance in patients with schizophrenia. J Clin Psychiatry. 2003; 63(12):1121-8. DOI: 10.4088/jcp.v63n1206. View